• Subscribe
  • Magazine
  • Videos
  • Advertise
  • About Us
  • Smart Water Summit
  • Wastewater Summit
    • Recent Quotes
    My Watchlist
    Indicators
    WaterWorld Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Iveric Bio Inc (NQ: ISEE )

    N/A UNCHANGED
    Last Price Updated: 4:00 PM EDT, Jul 10, 2023 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Iveric Bio Inc

    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Upward Trajectory For Biotech/Pharma M&A: Sector Trends Towards Pre-Pandemic Levels, Forecasts Positive For 2024
    According to the Global Data report, the pharma sector in Q3 2023 witnessed deals worth $28 billion, down 28% from the $54 billion recorded in Q2 2023.  
    Via Benzinga
    From AI to Obesity Drugs - Global Pharma Has $700B For M&A and Investments: Goldman Sachs
    Goldman Sachs compiled research suggesting the global pharmaceutical sector has approximately $700 billion available for M&A and investments. This significant financial reserve will be crucial as... 
    Via Benzinga
    IVERIC bio Inc. (NASDAQ: ISEE) Records 52-Week High Thursday Morning
    Via Investor Brand Network
    IVERIC bio Inc. (NASDAQ: ISEE) Making Surprising Moves in Monday Session
    Via Investor Brand Network
    The Latest Analyst Ratings for IVERIC bio
    Via Benzinga
    Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From IVERIC bio, Inc.
    Via Business Wire
    IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From IVERIC bio, Inc.
    Via Business Wire
    The Biotech Buying Bonanza: Why The FTC's Amgen Battle Won't Chill The Spree
    Big Pharma is facing a patent cliff that could siphon off billions in revenue. 
    Via Investor's Business Daily
    Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
    By David Willey, Benzinga 
    Via TheNewswire.com
    Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
    Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition? 
    Via News Direct
    Eye Care Sector Sees Several Large Acquisitions – Could This Ticker Be On Route For The Next Big Acquisition?
    The Japanese healthcare company Astellas Pharma, Inc. (OTC: ALPMF) recently announced its acquisition of the biopharmaceutical company Iveric Bio 
    Via Benzinga
    Why Shares of Annexon Are Plummeting Thursday
    Mixed trial results on a geographic atrophy eye drug led investors to sell the biotech stock. 
    Via The Motley Fool
    Iveric Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
    From IVERIC bio, Inc.
    Via Business Wire
    10 Health Care Stocks With Whale Alerts In Today's Session
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 4, 2023
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For May 3, 2023
    Via Benzinga
    IVERIC BIO INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of IVERIC bio, Inc. - ISEE
    From Kahn Swick & Foti, LLC
    Via Business Wire
    Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
    Via Benzinga
    Why Apellis Pharmaceuticals, TG Therapeutics, and Viking Therapeutics Were on the Move Today
    These three biotech stocks were on the volatile side today. 
    Via The Motley Fool
    BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Iveric Bio Inc. (Nasdaq – ISEE), Midwest Holding Inc. (Nasdaq – MDWT), Hoth Therapeutics, Inc. (Nasdaq – HOTH)
    From Brodsky & Smith LLC
    Via GlobeNewswire
    Benzinga's Top Ratings Upgrades, Downgrades For May 1, 2023
    Via Benzinga
    Biotech Buying Bonanza: Iveric Bio Snags $5.9 Billion Deal From Astellas Pharma
    The company is working on a treatment for the eye disease known as geographic atrophy. 
    Via Investor's Business Daily
    First Republic Folds Amid Banking Crisis, Elon Musk Expects Starship To Make Orbit On Next Launch, DOJ Probes Mastercard Over Anti-Competitive Debit-Card Practices: Today's Top Stories
    Benzinga 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    Nasdaq, S&P 500 Futures On Edge Over First Republic Failure, Tech Earnings: Analyst Pins Hopes On Fed's Next Move
    Stocks have reverted to their cautious ways on Monday amid a slew of market-moving catalysts. 
    Via Benzinga
    Astellas Pharma Acquires Iveric Bio For $5.9B To Focus On 'Blindness & Regeneration'
    Japanese healthcare company Astellas Pharma Inc (OTC: ALPMY) has agreed to buy Iveric Bio Inc (NASDAQ: ISEE) for $40.00 per share in cash for a total equity value of  
    Via Benzinga
    IVERIC bio, Ascendis Pharma And Other Big Stocks Moving Higher In Monday's Pre-Market Session
    U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Apollomics, Inc. (NASDAQ: APLM) surged 58.4% to $7.35 in pre-market trading... 
    Via Benzinga
    ISEE Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Iveric bio, Inc. Is Fair to Shareholders
    From Halper Sadeh LLC
    Via Business Wire
    Astellas Enters Into Definitive Agreement to Acquire Iveric Bio
    From IVERIC Bio, Inc.
    Via Business Wire
    < Previous 1 2 3 4 5 6 7 8 9 Next >
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.